Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Cabozantinib for patients with well diff G3 NETs…? What are the data? This analysis of the ALLIANCE A021602 – CABINET trial provides some information.
24 patients with G3 NETs, 16 on cabo and 8 on placebo. Primary sites: Pancreas (n=12); GI tract (n=7); unknown primary (n=3); lung/ thymus (n=2).
Median PFS for patients with G3 NET treated with cabozantinib was 7.9 months vs 3 months with placebo.
ORR: 25% (4/16) with cabozantinib vs. 0% (0/8) with placebo. No new safety signals.”
Title: Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)
Authors: Jonathan R. Strosberg, Tyler Zemla, Susan Geyer, Sydney Pulsipher, Fang-Shu Ou, Spencer Behr, Nitya Raj, Namrata Vijayvergia, Arvind Dasari, Eileen O’Reilly, Jeffrey A. Meyerhardt, Edward M. Wolin, Thorvardur R. Halfdanarson, Jennifer A. Chan
You can read the full article in Endocrine-Related Cancer.
More posts from Thor Halfdanarson.